ConductScience.org, home

Paper41576103

Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.

Rodrat M and 2 others. Proc Natl Acad Sci U S A, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant. Papers, record 41576103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41576103

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.
PubMed
Journal
Proc Natl Acad Sci U S A
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-08-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rodrat MMayureehttps://orcid.org/0000-0003-2062-8682
2Charlick JNJames Nhttps://orcid.org/0000-0001-9798-7769
3Sheppard DNDavid Nhttps://orcid.org/0000-0001-5533-9130

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cystic Fibrosis Transmembrane Conductance RegulatorMajor topic
Cystic FibrosisMajor topic
QuinolonesMajor topic
IndolesMajor topic
AminophenolsMajor topic
BenzodioxolesMajor topic
Humans
Pyridines
Drug Combinations
Mutation
Pyrazoles
Chloride Channel Agonists
Patch-Clamp Techniques
Pyrrolidines
Quinolines

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
SRC 021Cystic Fibrosis Trust (CF)PubMed

Source PubMed

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136499495Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy.Int J Mol Sci2022https://conductscience.org/library/papers/36499495PubMed
22475911Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.Science1989https://conductscience.org/library/papers/2475911PubMed
329903467Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.J Cyst Fibros2018https://conductscience.org/library/papers/29903467PubMed
41380673Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.Nature1992https://conductscience.org/library/papers/1380673PubMed
521825083Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.Thorax2012https://conductscience.org/library/papers/21825083PubMed
633775603Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.J Cyst Fibros2021https://conductscience.org/library/papers/33775603PubMed
730334692VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.N Engl J Med2018https://conductscience.org/library/papers/30334692PubMed
812069690The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.Biochem J2002https://conductscience.org/library/papers/12069690PubMed
929581173Structural mechanisms of CFTR function and dysfunction.J Gen Physiol2018https://conductscience.org/library/papers/29581173PubMed
1036543707Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background.J Cyst Fibros2023https://conductscience.org/library/papers/36543707PubMed
1131164398Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770.J Gen Physiol2019https://conductscience.org/library/papers/31164398PubMed
1233303536Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.Eur Respir J2021https://conductscience.org/library/papers/33303536PubMed
1331205003Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations.Elife2019https://conductscience.org/library/papers/31205003PubMed
1422406676Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR.J Mol Biol2012https://conductscience.org/library/papers/22406676PubMed
1515729345CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.Nature2005https://conductscience.org/library/papers/15729345PubMed
1636949202CFTR function, pathology and pharmacology at single-molecule resolution.Nature2023https://conductscience.org/library/papers/36949202PubMed
1731776420Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.Sci Rep2019https://conductscience.org/library/papers/31776420PubMed
1823891399Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.J Cyst Fibros2014https://conductscience.org/library/papers/23891399PubMed
1919846789Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19846789PubMed
2021486785The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR.J Physiol2011https://conductscience.org/library/papers/21486785PubMed

See all 62 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42357359Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics.Pharmaceutics2026https://conductscience.org/library/papers/42357359PubMed
41920076Altered functional interactions between CFTR disease mutants ΔF508 and G551D and the protein kinase A catalytic subunit.J Physiol2026https://conductscience.org/library/papers/41920076PubMed
41576103Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41576103PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CFTR1080PubTator's text mininghttps://conductscience.org/library/genes/1080

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41576103

GET https://conductscience.org/api/papers/v1/41576103/references?page=2